Close Menu

Sirius Genomics

Vancouver, Canada-based Sirius Genomics is using arrays to develop a test to identify individuals who respond to the hormone vasopressin and similar compounds for the treatment of septic shock.

The two firms will partner to develop diagnostics to identify individuals who respond well to Vasopressin and other compounds for the treatment of septic shock and related conditions.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

Pairings: Jun 30, 2010

Premium

Kamran Alam, Stan Lapidus

Pairings: Dec 9, 2009

Premium

Chris Wagner, Brad Popovich, Jorge Garces, Greg Hamilton, Nick Williams, Darren Hall

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

Sirius will work with a system of 37 hospitals to test biomarkers for severe sepsis drug response.

The Los Angeles Times reports that experts say Moderna's investigational COVID-19 vaccine results seem to be a step in the right direction, but that more testing is needed.

The Washington Post reports a new coronavirus data reporting protocol goes around the Centers for Disease Control and Prevention.

The Trump Administration has reversed its policy that could have stripped international students of their visas, the New York Times says.

In Cell this week: proteomic and metabolomic analysis of blood from COVID-19 patients, change in phosphorylation with infection, and more.